Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated June 25, 2020, reports the resolution of all outstanding Foreign Corrupt Practices Act (FCPA) investigations conducted by the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC). The filing addresses historical conduct involving current and former subsidiaries in Greece, Vietnam, South Korea, and China.
Key Financial Metrics
The filing details specific settlement payments required to resolve the investigations:
- Total Settlement Amount: USD 346.7 million
- Payment to DOJ: USD 233.9 million
- Payment to SEC: USD 112.8 million
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics, as this report focuses exclusively on legal settlements.
Material Changes and Settlement Details
The settlements resolve legacy compliance issues through the following agreements:
- Novartis Hellas DPA: A deferred prosecution agreement with the DOJ regarding inappropriate economic benefits provided to Greek healthcare professionals (2012-2015) related to the product Lucentis, and books and records issues.
- Alcon DPA: A separate deferred prosecution agreement with the DOJ for Alcon Pte Ltd (a former subsidiary) regarding inappropriate benefits to Vietnamese healthcare professionals and books and records violations (2011-2014).
- SEC Agreement: Resolves internal controls and books and records violations in Greece, Vietnam, and South Korea, as well as issues related to Alcon China's placement of surgical devices.
Novartis states that all outstanding FCPA investigations are now closed and that the company fully cooperated with the authorities.
Outlook, Risks, and Management Commentary
Management emphasizes that the settlements represent a milestone in resolving legacy compliance issues. Novartis has implemented remedial measures, including strengthened governance, principles-based compliance policies, and a reinforced "speak-up" culture.
Risks and Contingencies:
- Forward-looking statements regarding the successful implementation of ethical initiatives are subject to significant risks.
- There is no guarantee that the company will successfully comply with settlement terms or prevent future breaches.
- Potential adverse reactions from stakeholders, including healthcare professionals and customers, could impact the company.
- General risks include regulatory actions, pricing pressures, and the effects of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the total cash outflow of USD 346.7 million and its impact on the company's liquidity and earnings for the reporting period.
- Confirm the specific terms of the Deferred Prosecution Agreements (DPAs) with the DOJ for Novartis Hellas and Alcon.
- Review the status of the South Korea investigation, which the filing notes is in the "final stages" of resolution with local authorities.
- Assess the effectiveness of the newly implemented compliance and risk management functions mentioned by management.
- Monitor for any future regulatory actions or penalties related to the historical conduct described.